ERIC
european research initiative on CLL

39th General Assembly of ERIC members

Sunday, 6th of December 2015 (Orlando, Florida)

Agenda

07:30 – 08:00 EXECUTIVE COMMITTEE REPORT

- **Introduction, membership update and ERIC activities during 2015 – P. Ghia**
- **Update on the 1st Workshop in TP53 Analysis in CLL (Brno) – S. Pospíšilová**
- **Future TP53 Certification Rounds – S. Pospíšilová**

08:00 – 09:50 PROJECT UPDATES AND ANNOUNCEMENTS SESSION

09:50 – 10:00 OTHER MATTERS

ERIC Numbers

european research initiative on CLL

- Non-profit organization according to German law

  Klinik I für Innere Medizin, Universitätsklinikum Köln
  Kerpener Straße 62, 50937, Köln

- Hematology Department, Hospital Sant Pau,

  Mas Casanovas 90, 08041, Barcelona, Spain

- TAX ID Number (Steuernummer): 223/5905/0817
- VAT Number: DE300202219
- Bank Account at Deutsche bank in Köln

- PIC Number: 930535939

ERIC Membership

european research initiative on CLL

- 552 members
- Distributed amongst 46 countries
- Countries with most members:

United Kingdom (64)
Germany (53)
Italy (45)
Spain (45)

Czech Republic (43)
Sweden (37)
France (31)
Greece(29)

ERIC Membership

european research initiative on CLL



ERIC Membership

european research initiative on CLL

Number of ERIC members (by country)



Join ERIC

european research initiative on CLL

Please join ERIC if you are not a member already

- **Receive regular updates on ERIC activities**
- **Participate in ERIC projects**
- **Network with other CLL experts**
- **Get involved – it's free**
- **Join by going to our webpage, www.ericll.org and clicking on the membership tab**

Join ERIC

european research initiative on CLL



Eric Membership Application Form

Complete this form if you would like to become a registered ERIC member and receive further information about ERIC via email.

Contact Details

Title

First Name *

Last Name *

Institution *

Department

Address *

City *

Country *

Postcode *

Work Number *

Email Address *

Confirm Email Address *

Next

The new ERIC Online Membership Application Form

TP53 Network: Objectives

ERIC
european research initiative on CLL

ERIC aims to promote and/or advance the assessment of TP53 gene aberrations for diagnostic purposes by educating the hematological community about:

- **the need for performing such tests in all cases that require therapy, in both first and subsequent lines of treatment; and**

- **the quality of the appropriate techniques to be utilized by diagnostic laboratories to ensure reliable and comparable results across different institutions in Europe and elsewhere.**

TP53 Network: Plan of action

ERIC
european research initiative on CLL

1. **Face-to-Face Educational Activities**
   A. Tailored educational assistance to local laboratories through a reference labs network of ***Certifying*** **and** ***Training*** **Centers**
   B. Hands-on workshops (1st in Brno, October 1–2, 2015)

3. **Online Educational Activities**
   A. A **survey** to define current practices
   B. Setup, update and maintenance of an '**online help desk**'

www.ericll.org/pages/tp53network

TP53 Network: Structure

ERIC
european research initiative on CLL

TP53 Network: Structure

european research initiative on CLL

Training Centres

- Sarka Pospisilova, Brno, Czech Republic
- Fred Davi', Paris, France
- Stephan Stilgenbauer, Ulm, Germany
- Kostas Stamatopoulos, Thessaloniki, Greece
- Gianluca Gaidano, Novara, Italy
- Ramon Garcia Sanz, Salamanca, Spain
- Richard Rosenquist, Uppsala, Sweden
- David Gonzalez, London, United Kingdom
- Carsten Niemann, Copenhagen, Denmark
- Davide Rossi, Bellinzona, Switzerland
- Arnon Kater, Amsterdam, The Netherlands

Certifying Centres

Sarka Pospisilova, Brno, Czech Republic

Stephan Stilgenbauer, Ulm, Germany

Supported with an unrestricted grant from:

abbvie janssen GILEAD pharmacyclics

ERIC Publications in 2015

P Baliakas, A Hadzidimitriou, L-A Sutton, D Rossi, E Minga, N Villamor, M Larrayoz, J Kminkova, A Agathangelidis, Z Davis, E Tausch, E Stalika, B Kantorova, L Mansouri, L Scarfò, D Cortese, V Navrkalova, M J J Rose-Zerilli, K E Smedby, G Juliusson, A Anagnostopoulos, A M Makris, A Navarro, J Delgado, D Oscier, C Belessi, S Stilgenbauer, P Ghia, S Pospisilova, G Gaidano, E Campo, J C Strefford, K Stamatopoulos, R Rosenquist and on behalf of the European Research Initiative on CLL (ERIC)

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

Leukemia (2015) 29, 329–336; doi:10.1038/leu.2014.196

C. Moreno, M Montillo, P Panayiotidis, M Dimou, A Bloor, J Dupuis, A Schuh, S Norin, C Geisler, P Hillmen, M Doubek, M Trněný, P Obrtlikova, L Laurenti, S Stilgenbauer, L Smolej, P Ghia, F Cymbalista, U Jaeger, K Stamatopoulos, N Stavroyianni, P Carrington, H Zouabi, V Leblond, J C Gomez-Garcia, M Rubio, R Marasca, G Musuraca, L Rigacci, L Farina, R Paolini, S Pospisilova, E Kimby, C Bradley, E Montserrat

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Haematologica. 2015 Apr;100(4):511-6

ERIC Publications in 2015

european research initiative on CLL

Dreger P, Montserrat E; European Society for Blood and Marrow Transplantation (EBMT);European Research Initiative on CLL (ERIC).
Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?
Curr Hematol Malig Rep. 2015 Mar;10(1):59-64; doi: 10.1007/s11899-014-0242-1.

Montserrat E, Dreger P.
Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation.
J Clin Oncol. 2015 May 10; 33 (14):1527-29; doi: 10.1200/JCO.2014.60.3282.

Bystry V, Agathangelidis A, Bikos V, Sutton LA, Baliakas P, Hadzidimitriou A, Stamatopoulos K, Darzentas N; also on behalf of ERIC, the European Research Initiative on CLL.
ARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy.
Bioinformatics. 2015 Aug 6. pii: btv456. [Epub ahead of print]

Rawstron, A.
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for Minimal Residual Disease (MRD) detection in Chronic Lymphocytic Leukemia (CLL): an European Research Initiative on CLL (ERIC) study.

ERIC MEETINGS in 2016

- **ERIC General Assembly at ELN (Mannheim, Germany)**
  Date: February 2, 2016
  Time: 13:30-15:00 pm
  Location: Congress Center Rosengarten, Gustav Mahler III, Level 3

- **Educational Symposium of the European Expert Group on NGS Diagnostics in Lymphoid Malignancies(Joint initiative with EAHP, EHA)**
  Date: May 13th, 2016
  Location: Barcelona, Spain

- **6th Hands-on Workshop on IGHV gene mutations analysis**
  Date: September 15-17, 2016
  Location: Uppsala, Sweden

european research initiative on CLL

Symposium honoring Prof. Eva Kimby

A symposium to honor the lifetime achievements of Professor Eva Kimby, our esteemed colleague and ERIC board member, professor of Hematology at Karolinska Institutet, Stockholm, and senior consultant at the Centre for Hematology, Karolinkska University Hospital, was held on November 26th.

Agenda

08:00 – 09:50 PROJECT UPDATES AND ANNOUNCEMENTS

- **Update on the ERIC Gene Panel Project - where do we stand and where to go? - *L. Sutton***
- **Minimum Data Set Project - *C. Moreno and A. Hadzidimitriou***
- **Update on the study on Bendamustine and rituximab in CLL - *A. Cuneo***
- **Prognostic models in CLL-Accuracy and statistical significance – *P. Baliakas***
- **Expert forum for NGS diagnostics in lymphoid malignancies - a new joint ERIC/EHA/EAHP working group – *R. Rosenquist***

european research initiative on CLL

THANK YOU VERY MUCH FOR YOUR ATTENTION

With unrestricted support from

Celgene

vivia BIOTECH

pharmacyclics®